top of page
IPF Technology Specifications
Clinical Studies
Our IPF Technology has been tested in clinical studies at the National Center of Infectious and Parasitic Diseases in Bulgaria, and has shown promising antiviral and immunotherapy results.
Broad-Spectrum Antiviral Activity
Our IPF Technology has been shown to have broad-spectrum antiviral activity, targeting several viruses including influenza, HIV, and herpes simplex virus.
Patented Antiviral Peptide
Our patented antiviral peptide is based on the inactivated Pepsin Fragment (IPF) Technology, which has been shown to be safe and effective in preclinical studies.
Future Developments
We are constantly working to improve our IPF Technology and develop new treatments and preventions for viral infections. Stay tuned for updates on our research and development.
bottom of page